Intraperitoneal paclitaxel: A possible impact of regional delivery for prevention of peritoneal carcinomatosis in patients with gastric carcinoma

Hepato-Gastroenterology

Volumn 54, Issue 75, 2007, Pages 960-963

  Kodera, Yasuhiro ^a   Ito, Yuichi ^a   Ito, Seiji ^b   Ohashi, Norifumi ^a   Mochizuki, Yoshinari ^b   Yamamura, Yoshitaka ^b   Koike, Masahiko ^a   Fujiwara, Michitaka ^a   Nakanishi, Hayao ^b   Nakao, Akimasa ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Chemotherapy; Micrometastasis; Peritoneal carcinomatosis

Indexed keywords

ANTINEOPLASTIC AGENT; DEXAMETHASONE; DIPHENHYDRAMINE; FAMOTIDINE; PACLITAXEL;

ABDOMINAL PAIN; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASCITES; BONE MARROW SUPPRESSION; CANCER PREVENTION; CANCER RECURRENCE; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; HUMAN; MULTIPLE CYCLE TREATMENT; NAUSEA; PERITONEUM CANCER; POSTOPERATIVE CARE; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; STOMACH CARCINOMA; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA; HUMANS; INFUSIONS, PARENTERAL; PACLITAXEL; PERITONEAL NEOPLASMS; STOMACH NEOPLASMS;

EID: 34250171686     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Maruyama K, Kodera Y, Nakao A: Cancer of the Stomach. In Polluck RE, Doroshow JH, Khayat D, Nakao A, O'Sullivan B (Eds.). UICC Manual of Clinical Oncology. New Jersey: John Wiley & Sons, 2004.
2. Maehara Y, Hasuda S, Koga T, et al: Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancer. Br J Surg 2000; 87:353-357.
3. Yoo CH, Noh SH, Shin DW, et al: Recurrence following curative resection for gastric carcinoma. Br J Surg 2000; 87:236-242.
4. Bando E, Yonemura Y, Takeshita Y, et al: Intraoperative lavage for cytological examination in 1,297 patients with gastric carcinoma. Am J Surg 1999; 178:256-262.
5. Juhl H, Stritzel M, Wroblewski A, et al: Immunocytological detection of micrometasitatic cells: comparative evaluation of findings in the peritoneal cavity and the bone marrow of gastric, colorectal and pancreatic cancer patients. Int J Cancer 1994; 57:330-335.
6. Kodera Y, Nakanishi H, Ito S, et al: Quantitative detection of disseminated free cancer cells in peritoneal washes with real-time reverse transcriptase-polymerase chain reaction: a sensitive predictor of outcome for patients with gastric carcinoma. Ann Surg 2002; 235:499-506.
7. Kodera Y, Nakanishi H, Ito S, et al: Prognostic significance of intraperitoneal cancer cells in gastric carcinoma: detection of cytokeratin 20 mRNA in peritoneal washes, in addition to detection of carcinoembryonic antigen. Gastric Cancer 2005; 8:142-148.
8. Miyashiro I, Furukawa H, Sasako M, et al: No survival benefit with adjuvant chemotherapy for serosa-positive gastric cancer: randomized trial of adjuvant chemothereapy with cisplatin followed by oral fluorouracil in serosa-positive gastric cancer. Japan Clinical Oncology Group 920-6-2. Proc ASCO-GI 2005; 84: abstr 4.
9. Markman M: Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol 2003; 4:277-283.
10. Markman M, Rowinsky E, Hakes T, et al: Intraperitoneal administration of Taxol in the management of ovarian cancer. Monogr Natl Cancer Inst 1993; 15:103-106.
11. Francis P, Rowinsky E, Schneider J, et al: Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: A Gynecology Oncology Group pilot study. J Clin Oncol 1995; 13:2961-2967.
12. Fushida S, Furui N, Kinami S, et al: Pharmacologic study of intraperitoneal paclitaxel in gastric cancer patients with peritoneal dissemination. Gan To Kagaku Ryoho 2002; 29:2164-2167. (In Japanese with English abstract)
13. Longnecker SM, Donehower RC, Cates AE, et al: High performance liquid chromatographic assay for Taxol (NSC 125973) in human plasma and urine pharmacokinetics in a phase I trial. Cancer Treat Rep 1986; 71:53-59.
14. Ohashi N, Kodera Y, Nakanishi H, Yokoyama H, Fujiwara M, Koike M, Hibi K, Nakao A, Tatematsu M: Efficacy of intraperitoneal chemotherapy with paclitaxel targeting peritoneal micrometastasis as revealed by GFP-tagged human gastric cancer cell lines in nude mice. Int J Oncol 2005, 27:637-644.
15. Rowinsky EK, Donehower RC, Jones RJ, et al: Microtubule changes and cytotoxicity in leukemic cell lines treated with Taxol. Cancer Res 1988; 48:4903-4100.
16. Chang YF, Li LL, Wu CW, et al: Paclitaxel-induced apoptosis in human gastric cell lines. Cancer 1996; 77:14-18.
17. Fujitani K, Narahara H, Takiuchi H, et al: Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer. Oncology 2005; 69:414-420.
18. Tsuburaya A, Sakamoto J, Morita S, et al: A randomized phase III trial of post-operative adjuvant oral fluoropyrimidine versus sequential paclitaxel/oral fluoropyrimidine; and UFT versus S-1 for T3/T4 gastric carcinoma: the Stomach Cancer Adjuvant Multi-institutional Trial Group (SAMIT) trial. Jpn J Clin Oncol 2005; 35:672-675.